Substituted Stilbenes as Inhibitors of NF-kappaB and Activators of Nrf2

The present invention relates to substituted stilbenes and dienones which exhibit unexpected dual activity, as inhibitors of NFκB and as agonists (activators) of Nrf2. In particular, these compounds show dual activity and makes them particularly useful in the treatment of inflammation, including chr...

Full description

Saved in:
Bibliographic Details
Main Authors Deck, Lorraine M, Royer, Robert E, Vander Jagt, David L
Format Patent
LanguageEnglish
Published 30.05.2019
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention relates to substituted stilbenes and dienones which exhibit unexpected dual activity, as inhibitors of NFκB and as agonists (activators) of Nrf2. In particular, these compounds show dual activity and makes them particularly useful in the treatment of inflammation, including chronic inflammation and a number of related chronic disease states and conditions, including neurological diseases, including Alzheimer's, Alzheimer's prodrome and mild cognitive impairment, and other diseases and conditions, such as Parkinson's disease, depression, bipolar disorders and autism spectrum disorders. Compounds, pharmaceutical compositions and methods of treatment are described.
Bibliography:Application Number: US201816204085